Immunic, Inc. (IMUX) — insider trading
Health Care · NASDAQ
Immunic, Inc. (IMUX) has 12 reported SEC Form 4 insider transactions in our data (latest 2026-07-05).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-05 | Congleton Jon | Director | Grant / award / vesting (derivative) | 25,370 | $0.00 | $0 | Form 4 |
| 2026-07-05 | Neermann Joerg | Director | Grant / award / vesting (derivative) | 25,370 | $0.00 | $0 | Form 4 |
| 2026-07-05 | PHILLIPS BARCLAY A | Director | Grant / award / vesting (derivative) | 25,370 | $0.00 | $0 | Form 4 |
| 2026-07-05 | Rudick Richard Alan | Director | Grant / award / vesting (derivative) | 25,370 | $0.00 | $0 | Form 4 |
| 2026-07-05 | Skerjanec Simona | Director | Grant / award / vesting (derivative) | 25,370 | $0.00 | $0 | Form 4 |
| 2026-06-29 | Tardio Jason | Officer (President and COO) | Grant / award / vesting (derivative) | 253,000 | $0.00 | $0 | Form 4 |
| 2026-06-29 | PHILLIPS BARCLAY A | Director | Grant / award / vesting (derivative) | 25,370 | $0.00 | $0 | Form 4 |
| 2026-06-29 | Neermann Joerg | Director | Grant / award / vesting (derivative) | 25,370 | $0.00 | $0 | Form 4 |
| 2026-06-29 | HOWSON TAMAR D | Director | Grant / award / vesting (derivative) | 25,370 | $0.00 | $0 | Form 4 |
| 2026-06-29 | Rudick Richard Alan | Director | Grant / award / vesting (derivative) | 25,370 | $0.00 | $0 | Form 4 |
| 2026-06-29 | Skerjanec Simona | Director | Grant / award / vesting (derivative) | 25,370 | $0.00 | $0 | Form 4 |
| 2026-06-29 | Congleton Jon | Director | Grant / award / vesting (derivative) | 50,740 | $0.00 | $0 | Form 4 |
Ask the chat about IMUX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Immunic, Inc. (IMUX).
Last updated 2026-07-05 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.